Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;50(3):302-315.
doi: 10.1002/ppul.23146. Epub 2014 Dec 30.

Novel outcome measures for clinical trials in cystic fibrosis

Harm A W M Tiddens  1 , Michael Puderbach  2 , Jose G Venegas  3 , Felix Ratjen  4 , Scott H Donaldson  5 , Stephanie D Davis  6 , Steven M Rowe  7 , Scott D Sagel  8 , Mark Higgins  9 , David A Waltz  10
Affiliations
Review

Novel outcome measures for clinical trials in cystic fibrosis

Harm A W M Tiddens et al. Pediatr Pulmonol. 2015 Mar.

Abstract

Cystic fibrosis (CF) is a common inherited condition caused by mutations in the gene encoding the CF transmembrane regulator protein. With increased understanding of the molecular mechanisms underlying CF and the development of new therapies there comes the need to develop new outcome measures to assess the disease, its progression and response to treatment. As there are limitations to the current endpoints accepted for regulatory purposes, a workshop to discuss novel endpoints for clinical trials in CF was held in Anaheim, California in November 2011. The pros and cons of novel outcome measures with potential utility for evaluation of novel treatments in CF were critically evaluated. The highlights of the 2011 workshop and subsequent advances in technologies and techniques that could be used to inform the development of clinical trial endpoints are summarized in this review. Pediatr Pulmonol. © 2014 The Authors. Pediatric Pulmonology published by Wiley Periodicals, Inc.

Keywords: CFTR activity; cystic fibrosis; endpoints; imaging; outcome measures; sputum biomarkers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Stages of disease progression and pathologic changes that occur in the airways of patients with CF as they age, along with possible treatment approaches. Reprinted with permission of the American Thoracic Society. Copyright © 2014 American Thoracic Society. Ramsey BW. 2007. Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis. Proc Am Thorac Soc;4(4):359–63. Official Journal of the American Thoracic Society.
See this image and copyright information in PMC

References

    1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry. 2008 annual data report. Bethesda, Matyland. Last accessed 14 August 2013. http://www.cff.org/treatments/CareCenterNetwork/PatientRegistryReport/
    1. Ramsey BW. Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis. Proc Am Thorac Soc. 2007;4:359–363. - PMC - PubMed
    1. Yuksel H, Yilmaz O. A new model for cystic fibrosis management: control concept. Pneumologia. 2011;60:150–154. - PubMed
    1. Aurora P, Stanojevic S, Wade A, Oliver C, Kozlowska W, Lum S, Bush A, Price J, Carr SB, Shankar A. Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis. Am J Respir Crit Care Med. 2011;183:752–758. - PubMed
    1. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–1672. - PMC - PubMed